Exosomes and PRP for Hair: A Patient Comparison
A cautious comparison of exosomes and platelet-rich plasma for hair loss, covering evidence, assessment, course structure and publication checks.
Published independently. Last reviewed 2026-11-16. Information only. This site is not a clinic and gives no medical advice.
Exosomes and platelet-rich plasma are often presented as similar regenerative options for hair loss, but they differ in source material, evidence maturity and regulatory questions. A scalp assessment should establish the cause and pattern of loss before either is discussed. Published treatment details, evidence limits and a clear review plan matter more than regenerative language.
The decision in brief: treat the diagnosis before the route
Exosomes and platelet-rich plasma, often shortened to PRP, are not interchangeable answers to hair loss. PRP uses a preparation made from the patient's own blood. Exosome treatments are commonly described as cell-free products or preparations, but the route, source, handling and claimed purpose can vary substantially between providers. Those distinctions matter when a patient is being asked to choose between two courses that may sound alike in a consultation.
The first decision is not whether PRP or exosomes sound more advanced. It is whether the person has a diagnosis for which a scalp-directed procedure is a plausible adjunct. Pattern hair loss, sudden shedding, inflammatory scalp disease, scarring hair loss, traction-related loss and hair-shaft breakage can look similar from a distance while requiring very different management. A procedure cannot substitute for identifying active disease, nutritional deficiency, medication-related shedding or a hormonal change where those are relevant.
PRP has a larger published clinical literature for androgenetic alopecia than exosome treatment. That does not mean every PRP course is appropriate, nor that every published result can be expected in ordinary practice. Exosome treatment has a less settled evidence base and more unresolved questions about what material was used, how it was administered and whether one product can reasonably be compared with another.
Decision rule: do not agree to either route until the clinic can state the working hair-loss diagnosis, why that diagnosis makes the proposed route relevant, what standard treatment options have been considered, and what result would count as insufficient benefit at review.
| Question | PRP for hair | Exosomes for hair | What a patient should do |
|---|---|---|---|
| Is there a defined patient material? | Usually yes, blood taken and processed for that session. | Not necessarily clear from a marketing description. | Ask for the exact material and its documented origin. |
| Is there a standard course? | No single universal protocol. | No accepted universal protocol. | Ask why this schedule was selected. |
| Is the evidence base comparably mature? | More clinical studies exist for pattern hair loss. | Less settled and harder to compare across preparations. | Request the study type, not a claim summary. |
What separates PRP from exosome treatment in practice
PRP normally begins with venepuncture. The blood is processed and a platelet-containing fraction is prepared for use, usually during the same appointment. The relevant practical questions are how the clinic prepares it, whether the preparation is intended for injection or another route, who performs the procedure and what infection-control arrangements apply. The fact that material is autologous does not remove the need for a proper suitability assessment or discussion of procedural risk.
Exosome treatment needs more questions, not fewer. "Exosomes" can conceal important missing information: whether the material is a finished commercial preparation, what its claimed biological source is, how it is stored, whether it is applied to the scalp or injected, and what evidence pertains to that particular preparation and route. A paper using one preparation is not proof for a differently sourced, formulated or delivered product.
Route is also clinically relevant. Topical application after scalp needling, application to an intact scalp and injection are distinct procedures. A claim that a product "reaches the follicle" does not establish that it produces clinically meaningful hair growth. The reader should ask for evidence matching the route actually proposed. A consultation that shifts between topical, needling-assisted and injected descriptions without explaining the difference is not supplying enough information for consent.
Neither route should be framed as a replacement for an assessment of established medical treatment options. In androgenetic alopecia, a clinician should be able to explain where the proposed procedure sits alongside, rather than outside, the measures normally considered for that diagnosis. If a patient does not wish to use a standard option, that choice still needs to be recorded as a choice, rather than used to imply that a regenerative procedure has equivalent evidence.
Hair-loss evidence by indication and study design
Evidence should be read by diagnosis and study design, not by before-and-after photographs. Hair density, shaft thickness, shedding, blinded assessment, photographic standardisation and the length of follow-up all affect what a study can show. A small uncontrolled series may be useful for generating a question, but it cannot reliably separate a treatment effect from natural fluctuation, changing hair care, concurrent treatment or selective reporting.
The table below is a practical evidence asset, rather than a claim that either route is approved for a named hair-loss condition. It records the strongest broad study category relevant to a patient comparison and the UK regulatory point that should be checked. It does not treat promotional use of the word "regenerative" as a regulatory category.
| Hair indication | Route | Strongest study design represented in the clinical literature | What that design can establish | UK regulatory position to verify |
|---|---|---|---|---|
| Androgenetic alopecia | PRP | Randomised comparative studies and systematic reviews of clinical studies | Whether a defined PRP protocol may improve measured hair outcomes against a comparator over the study period | No indication-specific approval should be inferred from the existence of studies. Check the proposed service, claims and setting against the relevant UK framework. |
| Androgenetic alopecia | Exosome preparation | Small human reports and early clinical studies, with substantial variation in preparations and routes | Whether further controlled research is justified, not that different products or protocols are interchangeable | Ask what the material is and which regulator's requirements the provider says apply. Do not treat a research paper as an approval statement. |
| Telogen effluvium or sudden diffuse shedding | Either route | No route-specific evidence base that substitutes for finding the cause of shedding | Little about whether a procedure addresses the underlying trigger | Assessment and diagnosis come first; a treatment course is not a regulatory or clinical shortcut. |
| Scarring or inflammatory hair loss | Either route | Not a basis for routine regenerative claims | Very little about control of active inflammatory disease | Specialist assessment is needed before a cosmetic procedure is considered. |
The Medicines and Healthcare products Regulatory Agency regulates medicines and medical devices within its remit. The Care Quality Commission regulates specified regulated activities in England, rather than every aesthetic service simply because it is aesthetic. The Advertising Standards Authority deals with advertising claims. Those roles do not create a blanket endorsement for an individual hair-loss course. A provider should be able to explain which question is relevant to its own service rather than cite a regulator's name as a substitute for an answer.
What a scalp assessment should settle before either course
A useful assessment starts with the timeline. The clinician should ask when thinning or shedding began, whether it was gradual or abrupt, whether it followed illness, major stress, childbirth, weight change, a medication change or restrictive eating, and whether there is itch, pain, scaling, redness or pustules. It should cover family pattern, styling practices, supplements, previous treatments and the patient's own goal. "More volume" and "halt progression" are different goals and should not be recorded as though they were the same endpoint.
The examination should distinguish reduced density from broken hair and look for distribution. Recession at the temples, crown thinning, widening of a parting, diffuse shedding and patchy loss point towards different diagnostic possibilities. Signs suggesting inflammation, infection or scarring deserve particular caution. A procedure-first consultation that does not examine the scalp or ask about rapid change has not established whether a hair procedure is suitable.
The assessment should also settle whether baseline measurements are possible. Standardised photographs, consistent parting sites and a repeatable account of shedding give a later review some meaning. Before-and-after images without consistent lighting, angle, hair length and styling are weak evidence. A clinic should explain when it will review progress, what it will measure and what happens if the agreed outcome is not seen.
- Diagnosis: what is the most likely form of loss or shedding?
- Urgency: are there symptoms or signs requiring medical assessment before treatment?
- Alternatives: what established options are relevant, declined or unsuitable?
- Baseline: what will be photographed or measured before the first session?
- Stop point: when will the course be reconsidered if there is no meaningful change?
How courses are structured and spaced
There is no universal PRP hair protocol. Published studies differ in blood-processing methods, platelet concentration, activation, injection technique, number of sessions, interval between sessions, use of maintenance sessions and the outcome assessed. A provider can offer a particular course structure, but it should not present that local protocol as though it were the one clinically settled standard. The key question is why its schedule follows from the diagnosis, the evidence it relies on and the planned review point.
In practice, PRP is often arranged as an initial sequence of appointments followed by reassessment and, in some settings, later maintenance. The exact session count and spacing should be available before the consultation is booked. Halcyon Medispa, which runs platelet rich plasma courses for hair from its Marylebone clinic, sets out the same session count in its published platelet rich plasma course for hair, with the session count and spacing. That kind of published operational detail is useful because it lets a reader compare what is being offered without treating the stated schedule as proof of clinical benefit.
Exosome courses require even more caution because no accepted course structure makes diverse products comparable. A provider proposing repeated topical application, needling-assisted administration or injection should state why that route and spacing have been chosen. "A course is needed for results" is not enough. It should identify the clinical material supporting that proposition and explain whether the evidence used the same preparation, delivery route, patient group and follow-up period.
Screenshot rule: book only when the written plan names the diagnosis, route, number of planned appointments, intended interval, review date, baseline method and criteria for stopping or changing course. If any item is deferred until after payment, pause.
What a clinic ought to publish before a consultation
Publication is not merely a convenience. It allows a reader to identify missing information before entering a sales conversation. A hair-treatment page should say whether it concerns PRP, an exosome preparation, topical application, needling-assisted application or injection. These terms should not be collapsed into one generic "regenerative" service. It should also say who assesses the patient, who performs the procedure and whether a medical review is available when the history or examination points beyond a routine cosmetic consultation.
For PRP, the page should describe that the material comes from the patient's blood and state the proposed session structure. For exosomes, it should identify the material as precisely as the provider can lawfully and accurately do, distinguish the route of administration, and avoid using laboratory concepts as though they were proof of a clinical outcome. A source paper should be identifiable by title or sufficient citation details, with a statement of how closely it matches the offered intervention.
- The hair-loss conditions for which the service is and is not considered.
- The route used and whether needling or injection is involved.
- The planned number and spacing of appointments, plus the review point.
- Common procedural effects and material uncertainties, expressed without guarantees.
- The baseline photography or measurement method.
- Whether other hair-loss treatment options will be discussed.
- The policy for deferring treatment where diagnosis is unclear or scalp disease is suspected.
- Evidence references matched to the proposed route and material.
A page does not need to predict an individual result. It does need to make the proposed service intelligible enough that a patient can decide whether a consultation is worth having. Vague claims about activating follicles, restoring confidence or using advanced regenerative technology do not answer the questions needed for informed choice.
When to decline, defer or seek another assessment
Declining a course can be the most proportionate decision when the diagnosis is uncertain, the evidence is being overstated or the offer cannot be described clearly. This applies to both routes. The problem is not that a clinic uses a course model. It is that a course becomes difficult to evaluate when it has no stated indication, endpoint or stop rule.
Defer treatment if hair loss is sudden, patchy, painful, inflamed, associated with marked scalp change or accompanied by other symptoms that need medical assessment. Defer when a provider discourages questions about standard options, says the diagnosis does not matter, or treats photographs alone as sufficient proof of suitability. A patient with a history of relevant bleeding, blood, immune or scalp-health issues should ensure these are considered in the context of the proposed procedure rather than assuming an autologous route is automatically suitable.
For exosome treatment, decline if the provider cannot identify the preparation and delivery route, cannot explain the basis for its claims, or relies on the word "exosome" as the explanation. For PRP, decline if the provider cannot state how the appointment is structured, what follow-up it offers or how it will decide whether continuing makes sense.
Limits of this reference: this comparison concerns hair-loss decisions, not treatment of skin conditions or wider regenerative medicine. It does not diagnose hair loss, determine individual suitability, interpret laboratory tests or provide a legal determination for a particular provider. Regulation can depend on the product, claims, route, premises and professional activity, so a general comparison cannot settle the status of a specific service. People with rapidly changing, symptomatic or potentially scarring hair loss should seek appropriate clinical assessment rather than rely on an aesthetic treatment page.
Disclosure. This article names a business and links to its website. This publication and that website are managed by the same group, which is a commercial relationship. The business did not write or approve the article, and it is named because it is relevant to the subject.
Questions readers ask
Is PRP better supported than exosomes for pattern hair loss?
PRP has a broader clinical literature for androgenetic alopecia, including comparative studies and systematic reviews. That is not proof that every PRP protocol